Daniel Kingsbury
Pediatric Rheumatology · Portland, ORNPI 1396705414
Payments from drug & device makers
Across 287 payments — averaging $5332.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$552K
- AbbVie$333K
- Janssen Research & Development, LLC$205K
- Pfizer$131K
- UCB GmbH$125K
- Novartis Pharma AG$87K
- plus $97K from 3 others
Across 3 payments — averaging $2600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$8K
What the payments were for
- Speaking & faculty fees$4,095100%
- Food & beverage$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $552,154 |
| AbbVie | 112 | $333,381 |
| Janssen Research & Development, LLC | 62 | $205,411 |
| Pfizer | 57 | $131,030 |
| UCB GmbH | 9 | $124,791 |
| Novartis Pharma AG | 17 | $87,183 |
| E.r. Squibb & Sons, L.L.C. | 12 | $69,332 |
| Astrazeneca UK Limited | 2 | $27,220 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XELJANZ$950
How this compares
Too few pediatric rheumatology providers in Oregonto place this figure against a meaningful peer group, so we don't.
Other pediatric rheumatology in Portland
- Andrew LaskyPortland$118
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.